Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Hypopigmentation" patented technology

Hypopigmentation is characterized specifically as an area of skin becoming lighter than the baseline skin color, but not completely devoid of pigment. This is not to be confused with depigmentation, which is characterized as the absence of all pigment. It is caused by melanocyte or melanin depletion, or a decrease in the amino acid tyrosine, which is used by melanocytes to make melanin. Some common genetic causes include mutations in the tyrosinase gene or OCA2 gene. As melanin pigments tend to be in the skin, eye, and hair, these are the commonly affected areas in those with hypopigmentation.

A traditional Chinese medicine transdermal external preparation for treating vulvar hypopigmentation disease

ActiveCN121570548Breduce dilutionreduce churnAerosol deliveryOintment deliveryHypopigmentationAtrophy
The present application belongs to the technical field of traditional Chinese medicine composition, and relates to a traditional Chinese medicine transdermal external preparation for treating vulvar hypopigmentation disease. The preparation is a paste prepared by mixing traditional Chinese medicine powder and horse oil. The traditional Chinese medicine powder is composed of the following raw materials by weight: Xuchangqing 10-12, Pugongying 10-15, Difusiduo 12-15, Tuzifuding 12-15, Baiji 10-15, Huzhang 9-12, Quansie 6-10, Diyu 10-12, Xuezhi 10-12, Danggui 6-10, Rushang 6-10, Miedu 6-10, Bingpian 1-3. The traditional Chinese medicine transdermal external preparation has definite and significant effects on vulvar hypopigmentation disease, especially in relieving intractable pruritus, promoting pigment recovery and improving skin sclerosis / atrophy. The traditional Chinese medicine transdermal external preparation has high safety, few adverse reactions and low recurrence rate.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Melanocyte-regulating peptides

PendingAU2020325636B2MelanocyteHypopigmentation
The peptides of the invention have a sequence with at least 85% of identity with a sequence SEQ ID NO: 1 or 2. These peptides regulate melanocyte activity in terms of proliferation and production of melanin. Therefore, they are useful in the treatment of melanomas but also of cosmetic cutaneous hyper or hypopigmentation.
Owner:IDP DISCOVERY PHARMA SL

Traditional Chinese medicine transdermal external preparation for treating vulva hypopigmentation diseases

The invention belongs to the technical field of traditional Chinese medicine compositions, and relates to a traditional Chinese medicine transdermal external preparation for treating vulva hypopigmentation diseases. The traditional Chinese medicine powder is prepared from the following raw materials in parts by weight: 10 to 12 parts of radix cynanchi paniculati, 10 to 15 parts of herba taraxaci, 12 to 15 parts of fructus kochiae, 12 to 15 parts of rhizoma smilacis glabrae, 10 to 15 parts of rhizoma bletillae, 9 to 12 parts of rhizoma polygoni cuspidati, 6 to 10 parts of scorpion, 10 to 12 parts of radix sanguisorbae, 10 to 12 parts of dragon's blood, 6 to 10 parts of radix angelicae sinensis, 6 to 10 parts of frankincense, 6 to 10 parts of myrrh and 1 to 3 parts of borneol. The traditional Chinese medicine transdermal external preparation has an exact and remarkable curative effect on vulva hypopigmentation diseases, particularly has outstanding advantages in the aspects of relieving intractable itching, promoting pigment recovery and improving skin sclerosis / atrophy, and is high in safety, few in adverse reaction and low in recurrence rate.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Use of slc1a4 in the preparation of a medicament for treating a dyschromic skin disease

The application provides application of SLC1A4 in preparation of a medicament for treating a pigmentation abnormality skin disease, specifically, application of a reagent for detecting SLC1A4 as a detection reagent or a detection reagent kit for detecting a pigmentation abnormality skin disease, and application of an enhancer or inhibitor targeting SLC1A4 in preparation of a medicament for treating a pigmentation abnormality skin disease. The enhancer targeting SLC1A4 is a SLC1A4 overexpression plasmid, and the inhibitor targeting SLC1A4 is an SLC1A4 siRNA or shRNA. The pigmentation abnormality skin disease includes a hyperpigmentation skin disease and a hypopigmentation skin disease.
Owner:THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV